English
Home > Products > CAS NO 183288-46-2

China CAS NO 183288-46-2 Factory

We also present product or service sourcing and flight consolidation companies. We've our own manufacturing unit and sourcing office. We can easily provide you with nearly every form of merchandise similar to our product variety for CAS NO 183288-46-2,183288-46-2,Vilazodone intermediate,Vilazodone advance intermediate,5-(1-Piperazinyl)benzofuran, Welcome to visit us at any time for business relationship established.
CAS NO 183288-46-2, We aspire to meet the demands of our customers globally. Our range of solutions and services is continuously expanding to meet customers' requirements. We welcome new and old customers from all walks of life to contact us for future business relationships and achieving mutual success!

Related Products

Hot Products

  • Sodium carboxyl methylstarch

    Sodium carboxyl methylstarch

    Product Name:Sodium carboxyl methylstarch
    Molecular Formula:C2H4O3·xNa·x
    CAS Registry Number:9063-38-1
  • 1-(2,3-Dimethylphenyl)ethyl chloride

    1-(2,3-Dimethylphenyl)ethyl chloride

    Product Name:1-(2,3-Dimethylphenyl)ethyl chloride
    Molecular Formula:C10H13Cl
    Molecular Weight:168.66
    CAS Registry Number:60907-88-2
  • Ampicillin sodium

    Ampicillin sodium

    Product Name:Ampicillin sodium
    Molecular Formula:C16H20N3NaO4S
    Molecular Weight;373.4
    CAS Registry Number;69-52-3
  • Triphosphopyridine nucleotide

    Triphosphopyridine nucleotide

    Product Name:Triphosphopyridine nucleotide
    Molecular Formula:C21H28N7O17P3
    Molecular Weight;743.41
    CAS Registry Number;53-59-8
  • Hexamethyldisilane

    Hexamethyldisilane

    Product Name:Hexamethyldisilane
    Molecular Formula:C6H18Si2
    Molecular Weight:146.38
    CAS Registry Number:1450-14-2
  • R-tetrahydropapaverine HCl

    R-tetrahydropapaverine HCl

    Product Name:R-tetrahydropapaverine HCl
    Molecular Formula:C20H26ClNO4
    Molecular Weight:379.88
    CAS Registry Number:54417-53-7
  • Related Blog
  • Reviews

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products...

  • How much do you know about minocycline hydrochloride?

    Minocycline hydrochloride is commonly used as its hydrochloride, which is yellow crystalline powder, odorless, bitter in taste, and can cause deterioration when exposed to light. Soluble in water, slightly soluble in ethanol, easily soluble in alkali metal hydroxide or carbonate solution.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept